What are the benefits of adding anti-CD20 therapy to treatment with targeted agents in CLL?
During the Lymphoma, Leukemia & Myeloma 2021 Virtual Congress, the Lymphoma Hub was pleased to speak to Bruce Cheson, Georgetown University Hospital, Washington DC, US. We asked, What are the benefits of adding anti-CD20 therapy to treatment with targeted agents in chronic lymphocytic leukemia (CLL)?
Cheson begins by highlighting two trials that failed to show an advantage when adding rituximab to ibrutinib and current second generation anti-CD20s e.g. Obinutuzumab, which are shown to have some advantages over rituximab. Finally, he discusses the GENUINE trial where ublituximab was found to be superior to ibrutinib.
Видео What are the benefits of adding anti-CD20 therapy to treatment with targeted agents in CLL? канала Lymphoma Hub
Cheson begins by highlighting two trials that failed to show an advantage when adding rituximab to ibrutinib and current second generation anti-CD20s e.g. Obinutuzumab, which are shown to have some advantages over rituximab. Finally, he discusses the GENUINE trial where ublituximab was found to be superior to ibrutinib.
Видео What are the benefits of adding anti-CD20 therapy to treatment with targeted agents in CLL? канала Lymphoma Hub
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Why should we use checkpoint inhibitors with CAR-T therapy in DLBCL?
Meet Prof. Simon Rule of Derriford Hospital in Plymouth, UK
What are the promising updates in lymphoma at ASH 2019?
Prof. Gilles Salles | EBMT 2018 | Émergence de la thérapie cellulaire CAR-T dans les lymphome
What new chemo-free treatment options are emerging for follicular lymphoma?
Neurotoxicity from CAR T-cell therapy: why does it happen?
Case study Q&A: What is the optimum treatment in DLBCL?
What is in the pipeline for the treatment of T-cell lymphoma?
Astrid Pavlovsky | EHA 2018 | Key highlights from EHA on Hodgkin lymphoma
Christian Gisselbrecht | EBMT 2019 | Autologous stem cell transplant versus CAR T in R/R DLBCL
Pola-R-CHP vs R-CHOEP in young patients with high-risk DLBCL
Is CD47 a good target for immunotherapy in lymphoma?
Satellite Symposium | Patient with R/R DLBCL— US perspective
Satellite Symposium | Roundtable discussion, summary, and conclusions
What does the first-line data for polatuzumab vedotin tell us about its role in R/R DLBCL?
How effective is CAR T-cell therapy for R/R MCL in a standard-of-care setting?
Jean-Marie Michot| Key safety & efficacy outcomes of CC-122 & obinutuzumab study in R/R B-cell NHL?
The challenges for women in lymphoma: where there's a WiL, there's a way
Prof. Judith Trotman | ASH 2017 | BRIGHT study results
Astrid Pavlovsky explains why you should join the virtual Lymphoma Hub Satellite Symposium
What is the most promising novel agent for the treatment of aggressive B-cell lymphoma?